Regulation of High-fat Diet-induced Liver Fibrosis by SOCS1 Expression in Hepatic Stellate Cells.
暂无分享,去创建一个
[1] I. Mederacke,et al. An inducible model for genetic manipulation and fate-tracing of PDGFRβ-expressing fibrogenic cells in the liver , 2023, Scientific reports.
[2] P. Subramanian,et al. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease , 2023, Cellular and molecular gastroenterology and hepatology.
[3] J. Lazarus,et al. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. , 2023, Journal of hepatology.
[4] R. Schwabe,et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis , 2022, Nature.
[5] R. Kandhi,et al. An improved method for isolation and flow cytometric characterization of intrahepatic leukocytes from fatty and fibrotic liver tissues , 2022, Anatomical record.
[6] S. L. Friedman,et al. Hepatic Stellate Cell-Immune Interactions in NASH , 2022, Frontiers in Endocrinology.
[7] S. Friedman,et al. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future , 2021, Hepatology.
[8] H. Guillou,et al. New targets for NAFLD , 2021, JHEP reports : innovation in hepatology.
[9] S. Friedman,et al. Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.
[10] D. H. Ipsen,et al. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets? , 2021, Biomedicines.
[11] D. Brenner,et al. Heterogeneity of HSCs in a Mouse Model of NASH , 2021, Hepatology.
[12] B. Copple,et al. Liver fibrosis is driven by protease‐activated receptor‐1 expressed by hepatic stellate cells in experimental chronic liver injury , 2020, Research and practice in thrombosis and haemostasis.
[13] Y. Koyama,et al. Identification of Lineage-specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution. , 2020, Gastroenterology.
[14] D. Bobbala,et al. Essential role of suppressor of cytokine signaling 1 (SOCS1) in hepatocytes and macrophages in the regulation of liver fibrosis. , 2019, Cytokine.
[15] C. Meyer,et al. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019 , 2019, Cells.
[16] B. Fuchs,et al. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis , 2018, Scientific Reports.
[17] S. Friedman,et al. Hepatic stellate cells as key target in liver fibrosis. , 2017, Advanced drug delivery reviews.
[18] F. Tacke. Targeting hepatic macrophages to treat liver diseases. , 2017, Journal of hepatology.
[19] S. Friedman,et al. Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.
[20] M. Safran,et al. Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation , 2017, PloS one.
[21] F. Tacke,et al. Liver macrophages in tissue homeostasis and disease , 2017, Nature Reviews Immunology.
[22] Li-Rong Yu,et al. Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway* , 2017, The Journal of Biological Chemistry.
[23] A. Diehl,et al. Pathogenesis of Nonalcoholic Steatohepatitis. , 2016, Gastroenterology.
[24] D. Bobbala,et al. Negative regulation of the hepatic fibrogenic response by suppressor of cytokine signaling 1. , 2016, Cytokine.
[25] D. Torres,et al. Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis , 2015, Hepatology.
[26] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[27] C. Byrne,et al. NAFLD: a multisystem disease. , 2015, Journal of hepatology.
[28] M. Yeganeh,et al. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma , 2015, Oncogene.
[29] S. Friedman,et al. β-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis , 2015, Journal of hepatology.
[30] L. Rönnstrand,et al. SOCS proteins in regulation of receptor tyrosine kinase signaling , 2014, Cellular and Molecular Life Sciences.
[31] E. Casanova,et al. O147 HEPATIC STELLATE CELLS ARE THE MAJOR SOURCE OF COLLAGEN IN MURINE MODELS OF LIVER FIBROSIS , 2014 .
[32] R. Schwabe,et al. Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.
[33] A. Diehl,et al. NAFLD, NASH and liver cancer , 2013, Nature Reviews Gastroenterology &Hepatology.
[34] R. Schwabe,et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice , 2013, Hepatology.
[35] C. Tanaka,et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.
[36] S. Friedman,et al. Fibrosis‐dependent mechanisms of hepatocarcinogenesis , 2012, Hepatology.
[37] T. Kay,et al. Macrophage Deletion of SOCS1 Increases Sensitivity to LPS and Palmitic Acid and Results in Systemic Inflammation and Hepatic Insulin Resistance , 2011, Diabetes.
[38] A. Dalpke,et al. Suppressor of cytokine signaling 1 (SOCS1) limits NFκB signaling by decreasing p65 stability within the cell nucleus , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] Yosuke Osawa,et al. TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.
[40] P. Schirmacher,et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. , 2006, Journal of hepatology.
[41] Paul J Hertzog,et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation , 2006, Nature Immunology.
[42] M. Reiss,et al. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. , 2005, Molecular biology of the cell.
[43] S. Friedman,et al. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. , 2005, Journal of hepatology.
[44] J. Bonner,et al. Regulation of PDGF and its receptors in fibrotic diseases. , 2004, Cytokine & growth factor reviews.
[45] Takafumi Yoshida,et al. SOCS1 Is a Suppressor of Liver Fibrosis and Hepatitis-induced Carcinogenesis , 2004, The Journal of experimental medicine.
[46] Donald Metcalf,et al. SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.
[47] M. Kubo,et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. , 2002, Immunity.
[48] Warren S. Alexander,et al. Suppressors of cytokine signalling (SOCS) in the immune system , 2002, Nature Reviews Immunology.
[49] Gennaro Ciliberto,et al. Increased toxin‐induced liver injury and fibrosis in interleukin‐6–deficient mice , 2000, Hepatology.
[50] K. Okkenhaug,et al. Socs1 binds to multiple signalling proteins and suppresses Steel factor‐dependent proliferation , 1999, The EMBO journal.
[51] C. Trautwein,et al. Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.